Geovax announces initiation of phase 2 clinical trial of covid-19 vaccine booster in patients with chronic lymphocytic leukemia

Seeking improved immune response vs mrna vaccine atlanta, ga, july 20, 2023 (globe newswire) -- via newmediawire - geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the start of an investigator-initiated clinical trial (clinicaltrials.gov identifier:  nct05672355 ), titled “randomized observer-blinded phase 2 trial of covid-19 booster with geo-cm04s1 or pfizer-biontech bivalent vaccine in patients with chronic lymphocytic leukemia,” at city of hope national medical center, led by alexey danilov, m.d., phd as principal investigator.
GOVX Ratings Summary
GOVX Quant Ranking